Rho-kinase inhibitors in pseudophakic cystoid macular edema with secondary glaucoma

Abstract

Pseudophakic cystoid macular edema (PCME) is predominantly a self-limiting entity that can occasionally result in long-term visual deterioration. Rho-kinase (ROCK) inhibitors are therapeutic agents that have been successfully used for intraocular pressure (IOP) control in glaucoma patients and in the management of diabetic macular edema. In this report, we describe a case of mild nonproliferative diabetic retinopathy with PCME and secondary glaucoma. The patient presented with persistent PCME following scleral-fixated intraocular lens insertion, which was unresponsive to anti-vascular endothelial growth factor (anti-VEGF) agents and topical nonsteroidal anti-inflammatory therapy. A successful resolution of PCME was noted on 1-month follow-up after starting the patient on Rho-kinase inhibitors for secondary glaucoma.